⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for icos

Every month we try and update this database with for icos cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerNCT03989362
Cancer
Vopratelimab
Ipilimumab
18 Years - Jounce Therapeutics, Inc.
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsNCT02904226
Cancer
JTX-2011
Nivolumab
Ipilimumab
Pembrolizumab
18 Years - Jounce Therapeutics, Inc.
A Study of XmAb23104 in People With SarcomaNCT05879185
Sarcoma
XmAb23104
18 Years - Memorial Sloan Kettering Cancer Center
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerNCT03989362
Cancer
Vopratelimab
Ipilimumab
18 Years - Jounce Therapeutics, Inc.
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsNCT04319224
Cancer
Vopratelimab
Ipilimumab
Nivolumab
18 Years - Jounce Therapeutics, Inc.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: